Andrew M Shaughnessy

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Gold - Individuals: litigation

A force to be reckoned with on the pharmaceutical scene, Torys continues to perform flawlessly in patent matters. The team combines sophisticated prosecution, litigation and transaction expertise, and has representatives on all three tables. Recommended for patent procurement and deals, Eileen McMahon and Edward Fan earn warm feedback from their patrons: “Eileen is our go-to Canadian patent counsel. She consistently delivers extremely knowledgeable and pragmatic advice on a timely basis. She has a strong understanding of the pharmaceutical industry and of its accompanying intellectual property potential. We’ve had tremendous success in Canada, and it wouldn’t have been possible without Eileen’s help.” “Ed provides an excellent service, is client focused and incredibly strategic in his approach. He truly is a top-notch attorney who can handle complex patent prosecution mandates with ease.” Patent agent Teresa Reguly joined forces with lawyer Yael Bienenstock recently to represent Catalyst Pharmaceuticals and KYE Pharmaceuticals in the first case of its kind: a judicial review of the Minister of Health’s decision to overlook Catalyst’s drug data protection. The matter raises various questions about the legislative interpretation of the Food and Drug Regulations’ data protection requirements. They are not the only ones keeping busy: top-flight litigators Andrew Shaughnessy and Andrew Bernstein have been representing leading biotechnology company Amgen in proceedings before the Federal Court under the new PM(NOC) Regulations; Nicole Mantini linked up with Bernstein to support Nova Chemicals in its appeal at the Supreme Court, regarding a decision from the Federal Court where Dow Chemical was awarded hundreds of millions in damages.

Unlock unlimited access to all IAM content